Today, Representative Diana DeGette (CO-01), Co-Chair of the Congressional Diabetes Caucus, along with Representatives Mariannette Miller-Meeks (IA-01), Kim Schrier (WA-08), Rob Bresnahan (PA-08) , and Angie Craig (MN-02), introduced the Improving Needed Safeguards for Users of Lifesaving Insulin Now (“INSULIN”) Act. This bill will cap the cost of insulin at $35 per month for insured individuals.
Support the INSULIN Act to cap insured individuals' out-of-pocket insulin cost-sharing at $35 per month.
Occurrences
H.R. 10227 (IH) - Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026 - BILLS-119hr10227ih
Evidence
verified · Source version 65808 · locator 1347
Ms. DeGette (for herself, Mrs. Miller-Meeks, Ms. Schrier, Mr. Bresnahan, and Ms. Craig) introduced the following bill; which was referred to the Committee on Energy and Commerce
verified · Source version 52814 · locator 1626
For plan years beginning on or after January 1, 2028, a group health plan or health insurance issuer offering group or individual health insurance coverage shall provide coverage of selected insulin products
unverified · Source version 52814 · locator unknown
shall not-- ``(1) apply any deductible; or ``(2) impose any cost-sharing requirements in excess of, per 30-day supply
verified · Source version 52809 · locator 1159
introduced the Improving Needed Safeguards for Users of Lifesaving Insulin Now (“INSULIN”) Act. This bill will cap the cost of insulin at $35 per month for insured individuals.
verified · Source version 52816 · locator 1340
Reported by Mr. Cassidy, with an amendment, Mrs. Shaheen (for herself, Ms. Collins, Mr. Warnock, Mr. Kennedy
verified · Source version 52818 · locator 1521
The cost of a one-month supply of each Part B- and Part D-covered insulin product is no more than $35, and you don’t have to pay a deductible for insulin.
Assessments
Verified evidence shows DeGette introduced the INSULIN Act and the bill would create a $35 monthly insulin cap for insured individuals, with proposed coverage beginning for plan years on or after January 1, 2028. The verified record provided only shows introduction and committee referral, not enactment or implementation by the as_of_date. The existing Medicare $35 insulin cap is narrower than the promised insured-individuals outcome and is not tied by verified evidence to this commitment. Because this is documented material effort but not documented delivery, the outcome remains unresolved.